Compare
Integra Lifesciences Holdings Corp vs Penumbra Inc vs Teleflex Inc vs Haemonetics Corp
| Latest fiscal year | Integra Lifesciences Holdings Corp IART | Penumbra Inc PEN | Teleflex Inc TFX | Haemonetics Corp HAE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-28 |
| Revenue | $1.64B | $1.40B | $1.99B | $1.33B |
| Revenue growth (YoY) | +1.5% | +17.5% | +17.2% | -2.0% |
| Gross margin | 50.9% (computed) | 67.1% | 56.2% | 59.0% |
| Operating margin | -30.2% | 13.5% | 5.9% | 11.7% |
| Net margin | -31.6% | 12.7% | -45.4% | 7.3% |
| Net income | -$516.47M | $177.69M | -$905.64M | $97.31M |
| EPS (Diluted) | -$6.74 | $4.52 | -$20.25 | $2.05 |
| Operating cash flow | $50.38M | $238.66M | $96.68M | $293.22M |
| Free cash flow | -$31.05M | $174.93M | $1.45M | $260.44M |
| Cash & equivalents | $235.05M | $186.90M | $378.56M | $245.44M |
| Total assets | $3.60B | $1.83B | $6.95B | $2.40B |
| Total liabilities | $2.56B | $398.92M | $3.82B | n/a |
| Shareholders' equity | $1.04B | $1.43B | $3.12B | $796.32M |
| Return on year-end equity | -49.5% | 12.4% | -29.0% | 12.2% |
| Shares outstanding | n/a | 39.23M | n/a | 45.25M |
Revenue, most recent five fiscal years
| Fiscal year | Integra Lifesciences Holdings Corp | Penumbra Inc | Teleflex Inc | Haemonetics Corp |
|---|---|---|---|---|
| Latest | $1.64B Ended 2025-12-31 | $1.40B Ended 2025-12-31 | $1.99B Ended 2025-12-31 | $1.33B Ended 2026-03-28 |
| 1 year earlier | $1.61B Ended 2024-12-31 | $1.19B Ended 2024-12-31 | $1.70B Ended 2024-12-31 | $1.36B Ended 2025-03-29 |
| 2 years earlier | $1.54B Ended 2023-12-31 | $1.06B Ended 2023-12-31 | $1.71B Ended 2023-12-31 | $1.31B Ended 2024-03-30 |
| 3 years earlier | $1.56B Ended 2022-12-31 | $847.13M Ended 2022-12-31 | $2.79B Ended 2022-12-31 | $1.17B Ended 2023-04-01 |
| 4 years earlier | $1.54B Ended 2021-12-31 | $747.59M Ended 2021-12-31 | $2.81B Ended 2021-12-31 | $993.20M Ended 2022-04-02 |